PT  - JOURNAL ARTICLE
AU  - William Tillett
AU  - Lihi Eder
AU  - Niti Goel
AU  - Maarten De Wit
AU  - Dafna D. Gladman
AU  - Oliver FitzGerald
AU  - Willemina Campbell
AU  - Philip S. Helliwell
AU  - Laure Gossec
AU  - Ana-Maria Orbai
AU  - Alexis Ogdie
AU  - Vibeke Strand
AU  - Neil J. McHugh
AU  - Philip J. Mease
TI  - Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014
AID  - 10.3899/jrheum.141156
DP  - 2015 Nov 01
TA  - The Journal of Rheumatology
PG  - 2198--2203
VI  - 42
IP  - 11
4099  - http://www.jrheum.org/content/42/11/2198.short
4100  - http://www.jrheum.org/content/42/11/2198.full
SO  - J Rheumatol2015 Nov 01; 42
AB  - Objective. To discuss the need for revision of the “core set” of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.Methods. The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.Results. Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as “inflammatory musculoskeletal disease,” and nail and skin psoriasis as “psoriasis activity.”Conclusion. Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.